Please assess the completion status of the following clinical trial:

Trial Title: SOX as Salvage Treatment in Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range: 18-75 years old~* Histological confirmed incurable relapsed or metastatic nasopharyngeal carcinoma~* Prior exposure of at least one line of platinum-containing regimen~* ECOG performance status 0-1~* Life expectancy of more than 3 months~* Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧80g/L~* Liver function: total bilirubin, ALT and AST \<1.5×UNL~* Renal function: Cr\<1.5×UNL, CCR≧50ml/min~* Without \> 1 grade of neuropathy~Exclusion Criteria:~* With curable treatment option~* With CNS involvement~* Prior platinum exposure only in neo-adjuvant/adjuvant setting or concurrently used with radiotherapy~* Treated with \> 2 lines of palliative chemotherapy~* With prior exposure of S-1 or oxaliplatin~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Significant active infection~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- S-1 plus oxaliplatin (Type: EXPERIMENTAL): S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).